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Abstract
The archetypal epigenetic phenomenon of position effect variegation (PEV) in Drosophila occurs
when a gene is brought abnormally close to heterochromatin, resulting in stochastic silencing of
the affected gene in a proportion of cells that would normally express it. PEV has been instrumental
in unraveling epigenetic mechanisms. Using an in vivo mammalian model for PEV we have extensively
investigated the molecular basis for heterochromatin-mediated gene silencing. Here we distinguish
'epigenetic effects' from other cellular differences by studying ex vivo cells that are identical, apart
from the expression of the variegating gene which is silenced in a proportion of the cells. By
separating cells according to transgene expression we show here that silencing appears to be
associated with histone H3 lysine 9 trimethylation (H3K9me3), DNA methylation and the
localization of the silenced gene to a specific nuclear compartment enriched in these modifications.
In contrast, histone H3 acetylation (H3Ac) and lysine 4 di or tri methylation (H3K4me2/3) are the
predominant modifications associated with expression where we see the gene in a euchromatic
compartment. Interestingly, DNA methylation and inaccessibility, rather than H3K9me3,
correlated most strongly with resistance to de-repression by cellular activation. These results have
important implications for understanding the contribution of specific factors involved in the
establishment and maintenance of gene silencing and activation in vivo.
Background
Interphase eukaryotic nuclei contain two forms of chro-
matin [1]: densely DNA-stained regions termed hetero-
chromatin and more diffusely stained regions called
euchromatin. In contrast to euchromatin, heterochroma-
tin is rich in repetitive DNA elements, poor in transcrip-
tionally active genes, highly resistant to nuclease digestion
and the DNA replicates late in S-phase [2]. In mammals,
constitutive heterochromatin is enriched with specific
chromatin modifications including histone H3 lysine 9
(H3K9) trimethylation (me3) [3-5], H4K20me3 [6-8] and
DNA methylation [9-12], all of which have been impli-
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a coordinated manner. For instance, mice deficient in
Suv39h, a H3K9 histone methyltransferase (HMTase),
have reduced DNA methylation at their pericentric repeats
[11], indicating the interdependence between these mod-
ifications. Furthermore, the relationship between
H3K9me3 and DNA methylation has been implicated in
the regulation of genes involved in early development and
across species [13,14].
The gene-repressive effect of heterochromatin was first
demonstrated by position effect variegation (PEV) [15] in
Drosophila, where a normally euchromatic white+ gene
(responsible for red eye pigmentation) was silenced in a
proportion of eye cells when the gene was placed abnor-
mally close to a block of pericentric heterochromatin.
Similar phenomena were observed in organisms ranging
from yeast to mice when a reporter gene was inserted
within pericentric or telomeric regions of chromosomes
[16-18]. The extent of heterochromatin-induced silencing
effects can be modulated by the dosage of chromatin
modifiers. This was elegantly shown in the Saccharomyces
cerevisiae telomere position effect (TPE)[19,20]. In addi-
tion, mutations in genes encoding homologues of Suv39
[17,21-23] or a structural chromatin component [24-27],
heterochromatin protein 1 (HP1) [22,28-30], led to
reduced silencing of variegating reporter genes in Dro-
sophila and Schizosaccharomyces pombe. On the other hand,
enhanced/increased silencing of a variegating reporter
gene was observed with over-expression of Su(var)3-9
[21] or of an HP1 homologue in Drosophila, S. pombe and
mice [29,31,32].
Biochemical analyses in Drosophila and murine PEV
revealed that repressed variegating genes have a chroma-
tin structure and/or nucleosome organization pattern
comparable to constitutive heterochromatin of pericentric
regions [18,33,34]. Consistent with the spreading hypoth-
esis for heterochromatin formation, chromosomal rear-
rangement affecting two reporter genes resulted in
silencing of the reporter proximal to the rearrangement
breakpoint whenever the reporter distal to the breakpoint
was silenced [35,36]. This was accompanied by 'compac-
tion' visualized as the darkening of polytene chromosome
bands adjacent to the rearrangement breakpoint, suggest-
ing the spreading of heterochromatin over the breakpoint.
Based on these earlier observations, together with the sen-
sitivity of PEV to the dosage of chromatin modifiers, it has
been thought that PEV results from the stochastic spread-
ing of heterochromatin-forming factors or heterochro-
matic chromatin marks from a nearby heterochromatic
region into the variegating gene, in the absence of domi-
nant cis-acting boundary elements [37-39]. The spreading
of heterochromatin may occur in a linear manner or in
trans, where an interaction between a variegating gene and
heterochromatin on the same or another chromosome
occurs [40,41]. In a landmark study, Harmon and Sedat
demonstrated the correlation between silencing in Dro-
sophila PEV and the localization of the reporter to hetero-
chromatin [41]. However, there is little molecular
evidence for the spreading of 'heterochromatic' chromatin
modifications over a repressed variegating gene in verte-
brates.
Here, we investigated the chromatin modifications associ-
ated with a variegating transgene and dissected out their
roles in chromatin compaction and stable gene silencing,
using the variegating human CD2 (hCD2) transgenic
mouse system [18,31]. Our results revealed that repressed
variegating hCD2 transgenes are indeed associated with
known heterochromatic chromatin modifications,
including H3K9me3 and DNA methylation, and posi-
tioned within or close to a repressive nuclear domain.
However, DNA methylation was the key modification that
accompanied the formation of an inaccessible chromatin
structure and more stable gene silencing upon cellular
activation and through cell division.
Results
hCD2 transgenic mice as a model for mammalian PEV
In order to investigate chromatin modifications associ-
ated with a repressed hCD2 transgene, we used the CD2
1.3B and CD2 1.3A14 variegating mouse lines that have
been previously described [31]. Both these transgenic
lines carry an hCD2 transgene with a truncated locus con-
trol region (LCR - which is known to be necessary for
chromosomal position-independent expression of the
transgene) and have been shown to exhibit variegated
expression of hCD2 protein on the surface of T cells, irre-
spective of the orientation of the truncated LCR [18]. The
CD2 1.3B transgenic line contains six copies of hCD2
transgenes integrated within a block of pericentric major
satellite repeats. The CD2 1.3A14 transgenic line, on the
other hand, carries approximately 14 copies of the trans-
gene integrated close to, but outside, the pericentric hete-
rochromatin [31]. As seen with PEV in other organisms,
enhanced variegation was observed in these transgenic
mice in response to HP1β over-expression [31]. The fol-
lowing analyses were performed on sorted hCD2 express-
ing (hCD2+) and/or hCD2 non-expressing (hCD2-) T
cells isolated from mesenteric lymph nodes and spleens of
CD2 1.3B and CD2 1.3A14 transgenic mice (Figure 1A).
hCD2+ T cells from non-variegating CD2-LCR (called
here, minigene 4 (MG4)) transgenic mice [31] were also
used as controls for some analyses. It should be noted that
the level of surface hCD2 protein was previously shown to
correlate with hCD2 mRNA level [42].Page 2 of 17
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patterns similar to pericentric heterochromatin
Pericentric heterochromatin is enriched with H3K9me3
and contains few modifications associated with transcrip-
tional activation such as H3K9/K4Ac or H3K4me2/3. In
order to test whether repressed hCD2 transgenes have a
histone modification pattern comparable with pericentric
heterochromatin, we performed chromatin immunopre-
cipitation (ChIP) on chromatin prepared from sorted
hCD2+ and/or hCD2- T cells from CD2 1.3B and 1.3A14
transgenics, using antibodies against various histone
modifications indicated in Figure 1C. Enrichment for his-
tone modifications along the 8kb hCD2 transgene locus
was analysed by quantitative polymerase chain reaction
(PCR) using primer pairs for six different regions of the
transgene (Figure 1B). Controls were the β-actin and
CD3ε genes, which are transcribed in T cells, and the 5'
long terminal repeats (LTR) of intracisternal A particle
(IAP), which is a transposon element present in many
repressed copies in the murine genome. For each trans-
genic line, β-actin and CD3ε showed enrichment for
H3K4me2 and H3K9/K14Ac whereas IAP was mainly
enriched with H3K9me2/3, as anticipated (Figure 1D).
hCD2 transgenes in hCD2- T cells from both CD2 1.3B
and CD2 1.3A14 transgenic mice were enriched with
H3K9me3 and were markedly depleted in H3K4me2 and
H3K9/K14Ac (Figure 1C). In contrast, hCD2 transgenes in
hCD2+ T cells showed high levels of H3K4me2 and
H3K9/K14Ac (Fig. 1C). H3K9me1/2 was detected at the
transgene with similar levels in hCD2+ and hCD2- T cells
(Figure 1C). These modifications are not predominant
marks for pericentric heterochromatin [3-5]. Thus, the
repressed hCD2 transgene in both CD2 1.3B and CD2
1.3A14 transgenics have a histone modification pattern
similar to that of pericentric heterochromatin. However,
levels of H3K4me2 and H3K9/K14Ac were much lower
along the repressed transgenes in CD2 1.3B than those in
CD2 1.3A14 transgenic mice (Additional file 1, Figure
S3A). In CD2 1.3A14 transgenic mice, the H3K9me3 mark
was preferentially enriched at the coding and 3' regulatory
region, compared with the distal and proximal promoter
regions (Additional file 1, Figure S3B). This suggests that
the transgene in CD2 1.3B and CD2 1.3A14 transgenic
mice may be repressed by a mechanism involving
H3K9me3, but the mode of acquisition or maintenance of
this mark may differ between the two lines, as may the
nucleosome occupancy which would be interesting to
assess in more detail.
Key regulatory regions of repressed hCD2 transgenes are 
marked by DNA methylation
Despite its role in other forms of epigenetic silencing, such
as genomic imprinting, in mammals little is known about
the involvement of DNA methylation in PEV. However,
mammalian DNA methyltransferases have been reported
to localize at pericentric heterochromatin and can be
recruited to chromatin through known PEV modifiers
such as HP1 and Suv39h1 [11,43]. Therefore, we next
investigated whether DNA methylation is associated with
repressed hCD2 transgenes by analysing the DNA methyl-
ation pattern at the promoter and enhancer regions of the
hCD2 transgenes. The promoter of the hCD2 transgene
contains two CpGs approximately 100 bp upstream of the
transcriptional start site (Figure 2A). DNA methylation at
the CpGs was tested by digestion with a methylation-sen-
sitive restriction enzyme, HhaI and Southern blot (Figure
2B). The promoter CpGs were almost completely unmeth-
ylated (as indicated by 95%-100% digestion by HhaI) in
hCD2+ T cells from CD2 1.3B and MG4 transgenic mice
(Figure 2B). Notably, the promoter CpGs were highly
resistant to digestion with HhaI in hCD2- T cells from
CD2 1.3B and CD2 1.3A14 transgenic mice (about 5%
and 40% digestion, respectively), indicating a high level
of DNA methylation at the promoter CpGs of repressed
hCD2 transgenes (Figure 2B). In contrast to the promoter,
the enhancer region of the hCD2 transgene is relatively
CpG-rich. As shown in Figure 2C, there are 11 CpGs,
encompassing a region of 800 bp containing the 3' end of
Histone modification patterns of expressed and repressed hCD2 transgene in the CD2 1.3 variegating transgenic linesFigure 1 (see previous page)
Histone modification patterns of expressed and repressed hCD2 transgene in the CD2 1.3 variegating trans-
genic lines. (A) fluorescence-activated cell sorter (FACS) analysis of hCD2 expression on the surface of pre-sorted (green) 
and sorted (solid black) peripheral T cells. The hCD2 expression profile of non-transgenic T cells is shown in red. Chromo-
somal location of hCD2 transgene (orange circle) in each transgenic line is shown in the plots: pericentric regions and chromo-
some arms are shown as a black circle and white ovals respectively. (B) Schematic diagram of hCD2 transgene locus. Note that 
the 3' regulatory region is oriented in reverse directions in the CD2 1.3B and CD2 1.3A14 transgenic line. Locations of the 
primers used for chromatin immunoprecipitation (ChIP) assays are indicated with black bars and letters at the bottom. (C) 
ChIP analysis of histone modifications along the hCD2 transgene in hCD2+ and hCD2- T cells. ChIP was performed with chro-
matin prepared from sorted hCD2+ or hCD2- T cells from CD2 1.3B (white or black bar) and CD2 1.3A14 (grey bar) trans-
genics using antibodies against various histone H3 modifications. Enrichment for each modification was determined by qPCR 
and normalized to 5% input (black asterisks = P < 0.05, red asterisks = P < 0.005). This experiment was repeated three times 
(error bars = standard deviation). (D) control PCR on ChIP-ed materials using primers against expressed (CD3ε, β-actin) or 
repressed (IAP) loci.Page 4 of 17
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The DNA methylation status of the hCD2 transgene in hCD2+ and hCD2- T cells from the CD2 1.3 transgenic linesFigure 2
The DNA methylation status of the hCD2 transgene in hCD2+ and hCD2- T cells from the CD2 1.3 transgenic 
lines. (A) Schematic transgene map showing the restriction sites for BglII (B) and HhaI (H) and location of the probe used in B. 
(B) The CpG methylation analysis of the proximal promoter region by methylation-sensitive restriction enzyme digest and 
Southern blot. The bar charts show the ratios between the unmethylated and methylated HhaI sites. (C) Bisulfite sequencing 
analysis of the 3' regulatory regions of the hCD2 transgene. Methylated and unmethylated CpGs are shown as filled and open 
circles, respectively. Each line represents the sequence from a single clone. Similar results were obtained from two independ-
ent experiments. Comparisons between numbers of methylated CpGs were done using the Mann-Whitney U-test and Fisher's 
exact test (see text).
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of HSS2 (CpG site 5-11). HSS1 has previously been
shown to act as an enhancer [44]. DNA methylation status
of the 11 CpGs was analysed by metabisulfite sequencing.
Cytosine in most of the 11 enhancer CpGs in hCD2- T
cells was methylated at a high frequency, whereas, in
hCD2+ T cells, a large proportion of unmethylated
cytosines were observed at the enhancer CpGs (Figure 2C,
P = 0.0002 by the Mann-Whitney's U-test). This indicates
that, similar to DNA methylation at the promoter, the
enhancer region of repressed hCD2 transgenes is highly
methylated. Thus, we show here that DNA methylation
strongly correlates with gene silencing associated with
mammalian pericentric PEV. Interestingly, the most
marked difference in DNA methylation level among dif-
ferent hCD2- T cell populations was observed at CpG sites
1 and 2, which lie within or proximal to HSS1. In contrast
to other enhancer CpGs, DNA methylation at CpG sites 1
and 2 in hCD2- T cells was markedly reduced in the CD2
1.3A14 transgenic mice compared to these sites in the
CD2 1.3B mice (Figure 2C, PHSS1/HSS2 <0.05 by Fisher's
exact test). Hence, in addition to the difference in
H3K9me3 marking (Figure 1C), the pattern and level of
DNA methylation along repressed hCD2 transgenes also
seems to differ between the two transgenic lines.
A repressed hCD2 transgene is preferentially located at a 
repressive nuclear domain
The location of a gene within the nucleus has been impli-
cated in the regulation of its activity. In mammalian cells,
pericentric heterochromatin and the nuclear periphery
have been regarded as repressive nuclear domains [45,46].
To test whether the repressed state of the hCD2 transgene
correlates with its association with the repressive nuclear
domains, three-dimensional (3D) fluorescence in in-situ
hybridization (FISH) was undertaken on sorted hCD2-
and hCD2+ T cells from CD2 1.3B, 1.3A14 and MG4
transgenic mice. The pattern of hCD2 transgene localiza-
tion was divided into two categories: (1) not associated
with the heterochromatic major satellite DNA nor nuclear
periphery; and (2) close to, or associated with, the major
satellite DNA or nuclear periphery (as determined by 4',6-
diamidino-2-phenylindole (DAPI) counter-stain) (Figure
3A). The distance between the centre of a transgene signal
and the edge of the nearest major satellite cluster or
nuclear periphery was measured. hCD2+ and hCD2- T
cells from CD2 1.3A14 mice showed different distribu-
tions of the transgene signal relative to the nuclear periph-
ery and a pericentric cluster (Figure 3B, comparisons of
the distributions using the non-parametric Kolmogorov-
Smirnov test, P < 0.0001). The transgene in hCD2- T cells
from CD2 1.3A14 transgenic mice was found less than 0.4
μm from either the nuclear periphery or the major satellite
repeat (whichever was the closer) in approximately 75%
of cells (Figure 3C, for the details see Additional file 2,
Table S3). In striking contrast, the hCD2 signals in hCD2+
T cells from this transgenic line were not associated with
the major satellite and localized away from the nuclear
periphery in over 80% of cells (Figure 3C). Similar per-
centages of hCD2 signal distribution were observed with
hCD2+ T cells from the MG4 transgenic mice (approxi-
mately 70% not associated with the major satellite or
nuclear periphery, Figure 3C). Hence, in these transgenic
mouse lines, the nuclear localization of the hCD2 trans-
gene correlates with its expression status. With the CD2
1.3B transgenic line, in which the transgene is integrated
within the major satellite repeat, the nuclear localization
pattern of the hCD2 transgene also differed in expressing
and silent cells. The transgene signal was observed at the
periphery of a major satellite cluster in most hCD2+ T
cells from CD2 1.3B transgenic mice (data not shown),
whereas a transgene signal in hCD2- T cells from the mice
was undetectable by our 3D method. One possibility was
that the inability to detect the hCD2 transgene signal
might be due to the inaccessibility of the transgene locus
to the probe. To overcome this problem, and also to ana-
lyse the transgene location in the CD2 1.3B transgenic line
at a higher resolution, we performed FISH on ultrathin
(approximately 150nm thick) sections (cryo-FISH) of
FACS-sorted hCD2+ and hCD2- T cells from the trans-
genic mice (Figure 3D and 3E) [47]. First, we tested the
differences between the two distributions of distance of
the locus to the periphery of the nearest centromeric clus-
ter (Figure 3E). The hCD2 loci were more distant in the
hCD2+ than the hCD2- cells (comparisons of the distri-
butions using Kolmogorov-Smirnov test, P < 0.001).
When we compared the number of loci that were sepa-
rated from the periphery, we found that 47% of hCD2 loci
were >0.2 μm from the periphery of centromeric clusters
in hCD2+ cells compared to 11% in hCD2- cells (Chi-
squared test, P < 0.0001). Moreover, in 53% of hCD2- T
cells the hCD2 signal was observed within a major satel-
lite cluster compared to 23% in hCD2+ cells (Chi-square
test, P < 0.0001,). Taken together, the repressed hCD2
transgene in the CD2 1.3B transgenic line was more
closely associated with the major satellite cluster, whereas
the expressed counterpart appeared to be more frequently
'flipped out' from a major satellite cluster and positioned
at the surface of, or away from, the large block of pericen-
tric heterochromatin. This is reminiscent of observations
made with the pericentrically integrated λ5 transgene
[48].
Absence of the promoter but not the enhancer DNase I 
hypersensitivity correlates with the repressed status of the 
hCD2 transgene
We next investigated whether the chromatin modifica-
tions described above directly correlate with formation of
a higher-order chromatin structure over the hCD2 trans-
gene locus. The extent of chromatin compaction wasPage 6 of 17
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moter and enhancer regions of the hCD2 transgene
[18,42,44] in nuclei of sorted hCD2+ and hCD2- T cells
(Figure 4A). The promoter HSS was only detected in
nuclei of hCD2+ T cells from CD2 1.3B and MG4 but not
in hCD2- T cells from both CD2 1.3B and 1.3A14 trans-
genic mice. This is consistent with previously published
data from other variegating hCD2 transgenics [18,31,42]
(Figure 4B). Thus, the promoter HSS correlates with the
expression status of the hCD2 transgene. On the other
hand, the enhancer HSS (HSS1) was detected in the nuclei
of both hCD2+ T cells and hCD2- T cells from CD2
1.3A14 transgenic mice (Figure 4C). Only in nuclei of
hCD2- T cells from CD2 1.3B transgenic mice were both
the promoter and enhancer markedly resistant to DNase I
digestion (Figure 4B, C). The high accessibility of HSS1 to
DNase I in hCD2- T cells from the CD2 1.3A14 line
implied unstable nucleosomes and was rather surprising,
as the region was enriched with H3K9me3 which is nor-
mally found in inaccessible regions (Figure 1C). The dif-
ference in the accessibility of the enhancer HSS in hCD2-
T cells between CD2 1.3B and 1.3A14 transgenic mice
appears to correlate closely with the level of DNA methyl-
ation at the region (Figure 2C). Taken together, opening
of the promoter and enhancer HSSs may be necessary for
expression of the hCD2 transgene but repression of the
hCD2 transgene can be achieved by compaction of the
promoter HSS alone, irrespective of the presence or
absence of the enhancer HSS. Moreover, in combination
with results from the ChIP and bisulfite sequencing
assays, compaction of the enhancer HSS in this case might
be modulated by DNA methylation rather than
H3K9me3.
The stability of hCD2 transgene repression correlates with 
chromatin conformation at the enhancer
The classical definition of Drosophila PEV implies clonal
heritability of an on/off state of a variegating gene. How-
ever, a few previous studies have described some instabil-
ity of heterochromatic silencing in PEV and TPE [17,48-
50]. In fact, derepression of the hCD2 transgene was
observed in some T cells from CD2 1.3B transgenic mice
through cell divisions [51]. Hence, we took advantage of
this ability of an hCD2 transgene to derepress upon T cell
activation/proliferation to investigate whether the pre-
acquired chromatin modifications and chromatin confor-
mation (at the enhancer) might affect the stability of
hCD2 transgene repression. hCD2- T cells sorted from
CD2 1.3B and 1.3A14 transgenics were activated by T cell
receptor β (TCRβ) and CD28 co-stimulatory molecule
cross-linking for 1.5 or 3 days and changes in surface
expression of hCD2 protein were monitored by FACS
(Figure 5). For both the CD2 1.3B and CD2 1.3A14 trans-
genic lines, derepression of the hCD2 transgene was
observed with prolonged T cell activation, but the extent
of hCD2 derepression differed greatly between the two
transgenic lines. After 1.5 days of activation, the derepres-
sion of the hCD2 transgene was observed in around 7.4%
of hCD2- T cell population from CD2 1.3B transgenic
mice (Figure 5A). The percentage of the hCD2-dere-
pressed population almost doubled (12.6 ± standard
deviation [SD] 3.7%) after a further 1.5 days of activation.
The proportion of hCD2-derepressed T cells was very sim-
ilar to that described previously [51]. In contrast, hCD2- T
cells from CD2 1.3A14 transgenic mice exhibited much
more derepression of the hCD2 transgene (Figure 5B). At
the earlier time point, approximately 15% ± SD 9% of the
hCD2- T cell population from the transgenic mice dere-
pressed the hCD2 transgene but the proportion of hCD2-
derepressed T cells dramatically increased to approxi-
Nuclear localization of the hCD2 transgene in hCD2+ and hCD2- T cellsFigure 3 (see previous page)
Nuclear localization of the hCD2 transgene in hCD2+ and hCD2- T cells. (A, B, C) Three-dimensional fluorescence 
in in situ hybridization (FISH) analysis of the hCD2 transgene location in the nuclei of CD2 1.3A14 and MG4 transgenic T cells. 
(A) Deconvoluted images showing typical examples of two nuclear localization patterns of the hCD2 transgene (red) relative 
to γ-satellite clusters (green) and to the nuclear periphery (determined by DAPI-staining, blue). Bar: 5 μm. (B) The distance 
between the hCD2 transgene signal and the nearest γ-satellite clusters or nuclear periphery in CD2 1.3A14 hCD2+ and hCD2- 
T cells. The distance was measured from the centre of the transgene signal to the edge of a pericentric cluster or nuclear 
periphery. Median for hCD2+ T cells = 0.76 μm, that for hCD2- T cells = 0.29 μm. The difference in the distance of the trans-
gene signal from heterochromatin between hCD2+ and hCD2- T cells was statistically significant: P < 0.0001 by K-S test. (C) 
The percentage of hCD2+ and hCD2- T cells from the indicated transgenic lines that show close proximity of the transgene 
signal to heterochromatic nuclear compartments. The difference in the transgene location between hCD2+ and hCD2- T cells 
was statistically significant (P < 0.0001 by χ2 test). Note that as expected the difference in the transgene location between Mg4 
and CD2 1.3A14 hCD2+ T cells was not statistically significant (P > 0.05 by χ2 test). (D) The position of the hCD2 locus rela-
tive to the centromeric cluster was determined in sorted CD2+ and CD2- T cells, by cryoFISH using Rhodamine-labelled γ-sat-
ellite for detection of the centromeric cluster (red) and the DIG-labelled hCD2-cos1 cosmid probe to detect hCD2 loci 
(green). Nucleic acids were counterstained with TOTO-3 (blue). Bar: 2 μm. (E) The frequency of association of hCD2 locus 
with centromeric cluster were measured from the centre of the hCD2 signal to the periphery of the γ-satellite signal.Page 8 of 17
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DNase I hypersensitivity analysis on hCD2+ and hCD2- T cell nuclei from CD2 1.3B, CD2 1.3A14 and MG4 transgenic miceFigur  4
DNase I hypersensitivity analysis on hCD2+ and hCD2- T cell nuclei from CD2 1.3B, CD2 1.3A14 and MG4 
transgenic mice. (A) Transgene map showing locations of promoter (p) and enhancer HSSs, the restriction sites for BglII (B) 
and the probe locations. DNase I HSS at the hCD2 promoter (B) and enhancer (C) are indicated by red arrows. Black, blue 
and pink asterisks indicate transgene end-fragments, HSS2 and HSS3, respectively.
B B B B
HSSs
p
HSSs HSSs HSSs
p
3’ probe
5.8kb parent fragment
5’ probe
3kb parent fragment
*
*
*
**
*
CD2 1.3B
hCD2+
CD2 1.3B
hCD2-
CD2 1.3A14
hCD2-
MG4
CD2 1.3B
hCD2+
CD2 1.3B
hCD2-
CD2 1.3A14
hCD2-
MG4
5’ probe
3’ probe
A
B
C
Epigenetics & Chromatin 2009, 2:14 http://www.epigeneticsandchromatin.com/content/2/1/14
Page 10 of 17
(page number not for citation purposes)
Analysis of T cell activation-induced hCD2 derepression in hCD2- T cells from CD2 1.3B and CD2 1.3A14 transgenic miceFigure 5
Analysis of T cell activation-induced hCD2 derepression in hCD2- T cells from CD2 1.3B and CD2 1.3A14 
transgenic mice. The cells were activated for 1.5 and 3 days by TCRβ/CD28 cross-linking. Changes in the surface expression 
of hCD2 were monitored by FACS: pre-sort (green), post-sort (solid black) and non-transgenic (red). Accompanying numbers 
in FACS plots indicate the percentage of hCD2 expressing or derepressed T cells (± standard deviation).
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linking. For both transgenic lines, no marked hCD2 dere-
pression in hCD2- T cells was observed without TCRβ/
CD28 cross-linking (Figure 5A, B). Moreover, as the extent
of T cell activation and cell proliferation of the hCD2- T
cell population were comparable between the CD2 1.3B
and CD2 1.3A14 transgenic line (Additional file 3, Figure
S1), the difference in the degree of hCD2 derepression
reveals a difference in the susceptibility of the repressed
hCD2 transgene to derepression between these two lines.
The greater susceptibility of repressed hCD2 transgenes to
derepression in the CD2 1.3A14 transgenic line correlates
with the presence of the enhancer HSS and compromised
repressive chromatin 'marking' described earlier. In sup-
port of this, a similar instability of hCD2 transgene silenc-
ing was also observed with CD2 1.3-CTG transgenic mice
[42] and another CD2 1.3 transgenic mouse line where
hCD2- T cells exhibited high accessibility to DNase I at the
enhancer and extensive hCD2 derepression upon T cell
activation (Additional file 4, Figure S2 and data not
shown). In comparison with a study on the endogenous
Dntt locus [52], it is possible that the relatively long-range
spreading of chromatin marks and/or a compaction of
chromatin along the hCD2 transgene locus may be neces-
sary for the stable repression of the transgene. Taken
together, our results suggest that the CD2 1.3A14 and
1.3B transgenics differ in the detailed molecular mecha-
nisms for hCD2 repression, suggesting further complexity
of the mechanisms involved in 'heterochromatin-medi-
ated' silencing [53].
Discussion and conclusion
Epigenetic differences between expressed and repressed 
hCD2 transgenes
This report identifies specific chromatin marks associated
with an expressed and repressed variegating gene in vivo/
ex vivo in mammalian cells and correlates this with nuclear
localization of the repressed gene. Unlike previous studies
on Drosophila PEV, the use of hCD2+ and hCD2- T cells
from the individual CD2 1.3B transgenic mice enabled us
to examine 'pure' epigenetic differences between the
expressed and repressed hCD2 transgene. Consistent with
the previously observed sensitivity of PEV to Suv3-9
homologues [17,21-23], repressed hCD2 transgenes in
both CD2 1.3B and CD2 1.3A14 transgenic mice were
associated with H3K9me3 whereas expressed hCD2 trans-
genes were enriched with 'euchromatic' modifications
such as H3K4me2 and H3K9/K14Ac. We also demon-
strated that repressed hCD2 transgenes are embedded
within, or positioned close to, a repressive nuclear
domain whereas expressed transgenes are located away
from such a domain. Moreover, despite a previously
reported lack of correlation between DNA methylation
and variegation of a reporter gene in mice [54], our results
show that the relative abundance of DNA methylation at
the regulatory regions of a hCD2 transgene reflects the on/
off state of the hCD2 transgene. These observations sug-
gest that variegation of hCD2 transgenes involves multi-
ple layers of epigenetic regulation (Figure 6).
Distinct roles of H3K9me3 and DNA methylation in hCD2 
transgene silencing
The differences in the levels/patterns of repressive chro-
matin modifications/chromatin compaction along the
repressed hCD2 transgene and the stability of hCD2
repression in two different hCD2 transgenic lines (CD2
1.3A14 and CD2 1.3B) suggested an unequal contribu-
tion of DNA methylation and H3K9me3 to maintenance
of hCD2 repression. Although, we have not yet studied
nucleosomal occupancy directly, our results suggest that a
higher level of DNA methylation rather than H3K9me3,
correlates with compaction of the hCD2 regulatory
regions and more stable hCD2 repression. This is consist-
ent with recent studies which indicate that DNA methyla-
tion appears to prevent reactivation of GFP transgenes
[55] and developmentally regulated genes [56] in mam-
malian cells. However, it must be noted that the H3K9
HMTase, Suv39h, is an important factor in the establish-
ment of repression of the hCD2 transgene (S Uribe-Lewis,
unpublished data). Furthermore, it will be interesting to
study other histone modifications such as H3K27me3 and
H4K20me3 in the future. Taken together, different chro-
matin modifications might contribute differentially dur-
ing the initiation and maintenance stages of hCD2
repression.
Open enhancer conformation and instability of hCD2 
silencing
Conformation of the enhancer chromatin appears to cor-
relate with the stability of hCD2 repression during T cell
activation (Figure 4 and 5). It is possible that the open
enhancer conformation in CD2 1.3A14 transgenic mice
might lead to greater hCD2 derepression as trans-activa-
tors, which become up-regulated during T cell activation,
may bind to the enhancer and promote expression of a
previously repressed hCD2 transgene. Alternatively, inser-
tion into the major satellite sequences might lead to an
increased spreading of the heterochromatic state into the
CD2 1.3B transgene making it more resistant to derepres-
sion than the CD2 1.3A14 transgene array, which inte-
grated near to pericentric heterochromatin. Another
possibility is that the CD2 1.3A14 array is more subject to
the effect of transgene copy number whereas the pericen-
tric array is affected more by the satellite repeats [57]. Fur-
thermore, in accordance with recent descriptions of H3K9
demethylases [58-60], previously acquired H3K9me3 at
the enhancer may not be enough to keep the hCD2 trans-
gene in a repressed state if an H3K9 demethylase is
recruited to the region by an activator complex. In the case
of CD2 1.3B transgenic mice, compaction of the enhancerPage 11 of 17
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tors and further recruitment of activating chromatin mod-
ifiers making the hCD2 transgene more resistant to
derepression. In addition, as revealed by cryo-FISH,
embedding the repressed hCD2 transgene within the
highly heterochromatic environment in this transgenic
line might maintain a local abundance of heterochro-
matic factors high, which competitively prevent binding
of trans-activators to the transgene. However, even in the
CD2 1.3B transgenic line, the maintenance of hCD2 trans-
gene repression is incomplete and significant hCD2 dere-
pression occurs with prolonged T cell activation.
Interestingly, it has been reported that over-activation of
the JAK signalling pathway counteracts heterochromatic
silencing [61,62]. As the constitutive heterochromatin is
not completely inaccessible to molecules and is main-
tained by dynamic processes [63-66], the continuous
presence of a high level of trans-activators might eventu-
ally compete with heterochromatic factors and gain access
to binding sites on the hCD2 transgene to activate hCD2
expression [67]. Future work will address the role of a
growing number of histone modifications that may also
participate in these processes. In conclusion, our studies
on mammalian PEV have enabled us to dissect ex vivo
potential epigenetic factors associated with maintenance
of gene silencing through cell division and indicate that
DNA methylation correlates most strongly with both the
maintenance of inaccessibility and the transmission of
gene-silencing information to the daughter cell popula-
tion.
Materials and methods
Mice
All hCD2 transgenic mice lines were generated as previ-
ously described [18,31]. Transgenic mice that are hetero-
zygous for the hCD2 transgene were used for all the
experiments. The project was given ethical approval by
Imperial College London and the UK Home Office.
Cell sorting
Peripheral lymphocytes were obtained from mesenteric
lymph nodes and spleens of transgenic mice. T cells were
isolated from the mixed population using Dynal T cell
negative selection kit (Dynal, UK). hCD2+ T cells were
obtained by positive selection using MACS hCD2
microbeads (Miltenyi Biotec). The flow-through contain-
ing hCD2- T cells was further purified by incubation with
Dynal hCD2 magnetic beads (Dynal, UK) to deplete any
contamination with hCD2+ T cells. Alternatively, periph-
eral T cells were stained with an antibody cocktail contain-
ing phycoerythrin (PE)-conjugated anti-hCD2 (BD
Pharmingen), tri-colour (TC)-conjugated anti-CD4 and
Integrating nuclear position, histone modifications and accessibility of the gene in maintaining heterochromatin-mediated gene silencing in vivoFigu e 6
Integrating nuclear position, histone modifications and accessibility of the gene in maintaining heterochroma-
tin-mediated gene silencing in vivo. Different 'epigenotypes' (right) are depicted alongside the expression status (left) of 
the affected gene - DNA methylation and locus inaccessibility were found to have the strongest correlation with stable gene 
silencing.Page 12 of 17
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cence-activated cell sorter (FACS) DIVA (Becton Dicken-
son).
Cell culture
For cell culture, all the sorting procedures were carried out
under sterile conditions. Sorted hCD2- peripheral T cells
were resuspended in T-cell medium (Iscove's Modified
Dulbecco's Medium/10% fetal calf serum [Sigma
Aldrich]/1% penicillin/streptomycin/0.05% β-mercap-
toethanol/20 U/ml recombinant IL-2 [Roche], all from
GIBCO, unless indicated). For T-cell stimulation, 96-or
24-well plates were coated with 10 μg/ml anti-TCRβ chain
and 2 μg/ml anti-CD28 co-stimulatory molecules (BD
Pharmingen) in phosphate buffered saline (PBS). Cells
were cultured at 1 × 106 or 4 × 106 cells/well in 96- or 24-
well plates, respectively with or without T cell stimulation.
To measure the extent of cell proliferation, cells were
loaded with 1 μM carboxyfluorescin diacetate succinimi-
dylester (CFSE; Molecular Probes) in PBS prior to the cul-
ture.
FACS analysis
For ex vivo T cells, 1 × 105 cells were stained with PE-con-
jugated anti-hCD2 (1/200) and TC-conjugated anti-CD4
or CD8 (1/400) antibodies. For cultured T cells, 1 × 106 T
cells were stained with PE-conjugated hCD2, biotin-con-
jugated anti-CD69 (1/100) and allophycocyanin (APC)-
conjugated CD4 or CD8 (1/100; all from BD Pharmin-
gen) or with PE-conjugated hCD2, TC-conjugated CD4/
CD8 and APC-conjugated CD25 (1/100; BD Pharmin-
gen). For CD69 staining, cells were incubated with
cychrome-conjugated streptavidin (1/400; BD Pharmin-
gen) after staining with the primary antibody. Acquisition
and analysis were carried out using FACS Calibur and Cell
Quest software (Becton Dickinson). The cut-off point of
hCD2 expression level was set according to hCD2 fluores-
cence of CBA/Ca; >98% of T cells from the negative con-
trol fell below the cut-off point.
ChIP
ChIP was performed on sonicated chromatin prepared
from sorted T cells using standard protocols. Chromatin
was prepared from 5 × 106 sorted T cells. Cells were fixed
with 1% formaldehyde in X-linking buffer (50 mM 4-(2-
hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES)
pH8.0, 100 mM NaCl, 1 mM ethylenediaminetetraacetic
acid [EDTA], 0.5 mM ethylene glycol tetraacetic acid
[EGTA]) for 5 min. The X-linking reaction was quenched
by addition of 125 mM glycine/PBS. This was followed by
cell lysis and nuclear lysis in appropriate buffers. X-linked
chromatin was then sonicated on ice to produce 300-500
bp chromatin fragments. For each immunoprecipitation
(IP) sample, 2 μg chromatin was diluted to a final volume
of 375 μl in ice-cold IP buffer (1.1% Triton-X100, 0.01%
SDS, 1.2 mM EDTA, 167 mM NaCl, 20 mM Tris-HCl at
pH8.1, 10 mM Na butyrate, 0.1 mM phenylmeth-
anesulphonylfluoride, 0.1 mM Benzamidine, 1/1000 Pro-
tease inhibitors cocktail [Sigma-Aldrich, UK]) and was
incubated with 10 μg anti-dimethyl histone H3K4
(Abcam), 10 μg anti-acetyl histone H3 (Upstate Biotech-
nology), 10 μg normal rabbit IgG (Santa Cruz) or 5 μg
anti-mono-, di- or tri-methyl histone H3K9 (from Dr T
Jenuwein) for 3 h at 4°C on a rotator. 100 μl BSA-blocked
protein A-agarose beads (Upstate Biotechnology) was
added to each tube and incubated for further 1.5 h as
before. After the IP, the beads were washed twice each
with high salt, low salt and lithium chloride wash buffers.
The washed beads were resuspended in an elution buffer
and heated at 65°C for 30 min. Eluates were applied to
spin-X columns (Fisher Scientific) and spun at 6 k rpm for
2 min to remove the protein A beads. Input and bound
fractions were treated with RNase A and proteinase K
(both from Roche). IP-ed DNA was purified using Qiagen
PCR clean-up kit (Qiagen, UK). Purified IP-ed DNA was
diluted five times and purified input DNA was diluted 100
times in sterile H2O. For PCR with 'control' primers (IAP,β-actin and CD3ε), the reaction was performed with 5 μl
DNA, 1× PCR buffer (Sigma), 2 mM MgCl (Sigma), 0.4
mM dNTPs (Fermentas), 0.2 μM each forward and reverse
primer and 2.5 U Taq polymerase (Sigma) in a total vol-
ume of 20 μl. The PCR cycle was run as following: the ini-
tial incubation at 94°C for 5 min, 28 cycles (IAP) or 40
cycles (β-actin and CD3ε) of denaturing (94°C for 40 s),
annealing (60°C for 40 s) and extension (72°C for 36 s)
and the final extension at 72°C for 10 min. The PCR prod-
ucts were analysed by electrophoresis of the products on
1.5% TBE agarose gels. For real-time PCR analysis using
hCD2 primers, the reaction was carried out with 4 μl
DNA, 0.4 μM each forward and reverse primer and 1×
SYBR Jump-Start reaction mix (Sigma) in a total volume
of 20 μl. PCR cycles were set on and run through Opticon
1 or Opticon 2 program (MJ Research) connected to a PCR
cycler. The PCR cycle consisted of the initial activation of
Taq polymerase at 94°C for 2 min, 40 cycles of denaturing
(94°C for 30 s), annealing (60°C for 30 s) and extension
(72°C for 30 s). The fluorescence intensity was read at 75,
78, 80 and 82°C after each cycle. The analysis of resulting
C (t) values was performed using the Opticon1/2 pro-
gram. Threshold was set at 0.1, at which PCR amplifica-
tion curves were still in a linear range on a logarithmic
scale. C(t) values for samples and those for serial dilutions
of input DNA were read at this point. Standard calibration
curves were generated by plotting C(t) values against log
(arbitrary DNA concentration). This showed a linear cor-
relation between C(t) and log(DNA concentration) with
R2 value >0.95. The arbitrary DNA concentration of each
sample was calculated using equations generated from the
calibration curves. The resulting DNA concentration of
samples was normalized against input and enrichmentsPage 13 of 17
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input (1/20). The details of the antibodies and primers
used in the ChIP assays are shown in Additional file 2,
Tables S1 and S2.
Restriction enzyme digest/Metabisulfite sequencing
DNA was isolated from cells using a standard phenol-
chloroform extraction and ethanol precipitation protocol.
For methylation-sensitive restriction digest, DNA was
digested with BglII and HhaI (New England Biolab). Com-
pletion of genomic DNA digestion was controlled with λ
DNA (or a plasmid) digestion mixed with each reaction
mix. Digested genomic DNA was analysed by Southern
blotting using a [32P]dCTP-labelled hCD2 probe and ana-
lysed using a Phosphorimager (Amersham Pharmacia)
and Image Quant software (Molecular Probes). For meta-
bisulfite sequencing, DNA was digested with AflII and/or
XbaI. Digested DNA was denatured by heating and treat-
ment with NaOH and then treated with sodium bisulfite
(Sigma). Nested PCR was performed using an Expand
High Fidelity PCR kit (Roche) to amplify fully converted
DNA templates. PCR products were cloned into a TA-clon-
ing vector (Invitrogen). Approximately 30 clones were
sequenced to determine the methylation status for each
sample. Only the clones that showed >97% C->T conver-
sion at non-CpG sites were used for analysis.
DNase I hypersensitivity assay
DNase I hypersensitivity assay was carried out as
described previously [18,31,42]. The extent of DNase I
digestions were determined by 0.7% agarose gel electro-
phoresis of digested DNA samples.
3D-FISH
For 3D FISH, 1-2 × 105 cells were stuck to poly-L-lysine-
covered coverslips and fixed with 0.1% glutaraldehyde in
fix/permeabilization buffer (20 mM KH2PO4, 130 mM
NaCl, 20 mM KCl, 10 mM EGTA, 2 mM MgCl2, 0.1% Tri-
ton-X100) for 30 min at RT. Fixation was quenched by
treatment with Na borohydride. Cells were re-fixed with a
mixture of EGS and sulfo-EGS before in situ denaturation
of genomic DNA. hCD2 probe and γ-satellite probe were
labelled using digoxigenin (DIG)-Nick Translation Mix
(Roche) or with fluorescein-dUTP using Nick Translation
Mix (Roche), respectively. Labelled probes were mixed
with mouse-Cot1 DNA and salmon sperm DNA in FISH
hybridization mix (50%(v/v) formamide, 2 × SSC, 10%
dextran sulfate, pH7.2). Genomic DNA was denatured in
situ by treatment with CAPS:NaOH solution (pH12.85-
13.10) for 2 min and hybridized with heat-denatured
probes for overnight-48 h at 38°C in a humidified cham-
ber. Cells were washed extensively with 1-2× SSC/0.05%
Tween-20. Signal from DIG-labelled hCD2 probe was vis-
ualized by treatment with sheep anti-DIG antibody
(GIBCO), followed by rhodamine-conjugated donkey
anti-sheep IgG antibody (Jackson Laboratories). After
washes with 4 × SSC/0.05% Tween-20, cells were stained
with DAPI (100 ng/ml) and mounted in Vectashield.
Images were acquired and analysed using a DeltaVision
System and Soft RoRx software (Applied Precisions). The
experiments were conducted in a blind manner.
Cryo-FISH
Ultracryosectioning and FISH was performed essentially
as described in [47]. Resting T cells from hCD2 1.3B
lymph nodes were fixed in 4% and 8% paraformaldehyde
in 250 mM HEPES (pH 7.6; 10 min and 2 h, respectively)
[68]. Cell pellets were embedded in 2.1 M sucrose in PBS
and frozen in liquid nitrogen. Cryosections were cut using
an UltraCut UCT 52 ultracryomicrotome (Leica, Milton
Keynes, UK) with 200 nm in thickness, captured in
sucrose drops, and transferred to coverslips for cryo-FISH.
Probes used to label pericentromeric clusters (γ- satellite
plasmid; from Dr N Dillon) and human CD2 (hCD2-cos1
construct; from Dr D Kioussis) were labelled with DIG
and biotin by nick translation (Roche), respectively, and
separated from unincorporated nucleotides using micro-
BioSpin P-30 chromatography columns (BioRad, UK).
Hybridization mixtures contained 50% deionized forma-
mide, 2 × SSC, 10% dextran sulphate, 50 mM phosphate
buffer (pH 7.0), 1 μg/μl human Cot1 DNA, 2 μg/μl
salmon sperm DNA, 1 μl nick-translated γ- satellite and 4
μl hCD2-cos1 DNA (in 6 μl hybridization buffer). Probes
were denatured at 70°C for 10 min, and reannealed at
37°C for 30 min before hybridization. Cryosections were
rinsed (three times in PBS, incubated (30 min) in 20 mM
glycine in PBS, rinsed (three times) in PBS, permeabilized
(10 min) with 0.2% Triton X-100 +0.2% saponin in PBS,
and then washed (three times) in PBS. After washing with
PBS, cryosections were incubated (1 h, 37°C) with 250
μg/ml RNase A, treated (10 min) with 0.1 M HCl, dehy-
drated in ethanol (50% to 100% series, 3 min each),
denatured (12 min, 80°C) in 70% deionized formamide,
2×SSC and dehydrated as above. Hybridization was car-
ried out at 37°C in a moist chamber for >40 h. Posthy-
bridization washes were as follows: 50% formamide in
2×SSC (42°C; three times over 25 min), 0.1× SSC (60°C,
three times over 30 min) and 4×SSC with 0.1% Tween-20
(42°C, 10 min). Sections were incubated (30 min) with
casein-blocking solution (Vector Laboratories) containing
2.6% NaCl, 0.5% BSA, 0.1% fish skin gelatin, pH 7.5-8.0).
The γ-satellite signal was amplified (2 h) with sheep Fab
fragments anti-DIG (Roche), washed (three times over 1
h), incubated (1 h) with Cy3-conjugated donkey antibod-
ies anti-sheep IgG (Jackson Laboratories). The hCD2 sig-
nal was amplified (1 h) with AlexaFluor488 Neutravidin
(Molecular Probes, Eugene, OR), washed (three times
over 1 h), incubated (1 h) with biotinylated goat anti-avi-
din antibodies (Vector), washed (three times over 1 h),Page 14 of 17
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casein-blocking solution. Nuclei were counterstained
with 2 μM TOTO-3 (Molecular Probes) in PBS/0.05%
Tween-20, washed (four times) in PBS and mounted in
VectaShield.
Hybridization of non-transgenic cells with hCD2 probes
showed no detectable signals.
Images (TIFF files) were acquired on a confocal laser scan-
ning microscope (Leica TCS SP2; 100× objective, NA 1.4,
Milton Keynes, UK), equipped with Argon (488), HeNe
(543 nm) and HeNe (633 nm) lasers, and pinhole equiv-
alent to 1 Airy disk. Images (TIFF files) from the different
channels were collected sequentially to prevent
bleedthrough.
Statistical analysis
Students t-test (unpaired, two-tailed), Fisher's exact test
and Chi-squared test were carried out using GraphPad
Software http://www.graphpad.com and Mann-Whitney's
U-test was performed using VassarStats http://faculty.vas
sar.edu/lowry/utest.html. Also, non-parametric Kol-
mogorov-Smirnov test was carried out using an online cal-
culator http://www.physics.csbsju.edu/stats/KS-test.html.
Statistical methods used in particular analyses are stated
in the main text or figure legends.
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